Teledyne Technologies Free cash flow decreased by 39.8% to $204.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.0%, from $224.60M to $204.30M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 10.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $190.50M | $163.60M | $261.60M | -$237.70M | $176.10M | $252.20M | $203.60M | $178.60M | $163.20M | $255.20M | $124.20M | $275.10M | $301.00M | $228.70M | $303.40M | $224.60M | $196.30M | $313.90M | $339.20M | $204.30M |
| QoQ Change | — | -14.1% | +59.9% | -190.9% | +174.1% | +43.2% | -19.3% | -12.3% | -8.6% | +56.4% | -51.3% | +121.5% | +9.4% | -24.0% | +32.7% | -26.0% | -12.6% | +59.9% | +8.1% | -39.8% |
| YoY Change | — | — | — | — | -7.6% | +54.2% | -22.2% | +175.1% | -7.3% | +1.2% | -39.0% | +54.0% | +84.4% | -10.4% | +144.3% | -18.4% | -34.8% | +37.3% | +11.8% | -9.0% |